News

Tue, 04/12/2018
SFB 128 International Symposium
SFB 128. We are happy to announce the international Symposium of the Collaborative Research Centre 128 “Multiple Sclerosis” taking place from Sunday, September 15th, till Tuesday, September 17th, 2019 in the Rhine Main region. Full details of the event will follow....more
Fri, 26/10/2018
Featured publication: Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk
In a large multi-cohort study, performed by the International Multiple Sclerosis Genetics Consortium (IMSGC) and published in Cell Magazine, unexplained heritability for multiple sclerosis (MS) is detected in low-frequency coding variants that are missed by genome-wide association study (GWAS) analyses, further underscoring the role of immune genes in MS pathology. The IMSGC was formed in […]...more
Tue, 09/10/2018
Munich Cluster for Systems Neurology (SyNergy) will be funded
Munich. The Cluster for Systems Neurology (SyNergy) by LMU and TUM will receive funding from 2019 on. Currently SFB PIs Prof. Reinhard Hohlfeld, Prof. Martin Kerschensteiner, Prof. Mikael Simons are also PIs of SyNergy projects....more


Tue, 21/04/2015 | Nina Wettschureck awarded prize for mechanistic elucidation of MS therapy

Nina Wettschureck (MPI Bad Nauheim) from the CRC-TR-128, together with Markus Schwaninger (University of Lübeck), has been awarded the Novartis prize for therapy-relevant pharmacological research. The prize, which carries a value of €10,000, was presented at the Annual Conference of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) on 12 March 2015 in Kiel.

More details can be found in this press release, and the research for which the prize was awarded was reported in the following publication in The Journal of Clinical Investigation:

Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Köhl J, Offermanns S, Wettschureck N, Schwaninger M: Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. The Journal of Clinical Investigation. doi:10.1172/JCI72151